62 views
When Professor Sir Nick White arrived in Thailand from Oxford University 40 years ago to enroll in a small medical study unit, his duties included treating malaria and trafficking in toxic snakes. Today, from his base at Mahidol University in Bangkok, he leads a foreign team leading a global COVID-19 drug trial.
“We are doing this from Thailand because we have reveled here for wonderful multinational testing,” said Sir Nick, who is a professor at Oxford and Mahidol and knighted in 2017 through Queen Elizabeth British for her global fitness services, said in a statement. interview. . « Thailand outperforms its weight in clinical medical research. It has a very intelligent educational criterion and has created an environment that values innovation, creativity and knowledge.
Thailand has long been identified around the world as a destination for so-called medical tourists attracted by Bangkok’s world-class hospitals. Less well known is an underlying healthcare ecosystem that is helping Southeast Asia’s largest economy in a much larger medical facility, attracting investors and biotechnology researchers, adding vaccines, genomics and biopharmaceuticals, as well as high-tech medical devices.
While the COVID-19 pandemic has paralyzed industries in other parts of the world, it has in fact strengthened investor confidence in Thailand’s fitness care sector. In the first part of 2020, 52 medical corporations with projects cost thirteen billion baht (more than $400 million) sought approval from the Thai Investment Council (BOI): a 170% increase in the number of projects and a 123% increase in price over the same era last year.
In a recent example, Genexine Inc. , South Korea’s largest biotechnology company with a $2. 5 billion market, partnered with a Thai public-private consortium to create KinGen Biotech, a manufacturer of cancer drugs and DNA vaccines for cervical cancer.
KinGen targets annual sales of $250 million through 2026. “BoI is a great support for our project,” says Kim Kyu Don, Genexine’s CHIEF Financial Officer. “Our sales goal is ambitious and also very achievable. “
KinGen aims to use Thailand as a center of study and progression, as well as a production base for Southeast Asia, the Middle East, Africa, Latin America and Russia. “The Thai medical sector has wonderful potential,” Kim added. “We need to make the generation grow more. “
Another company that has just won from BOI is Apsalagen Co. Ltd. , a joint venture between Thai company Siam Bioscience and Germany’s Haase Investment, the main shareholder of Berlin-based Biotechrabbit GmbH. (RT-PCR) for COVID-19 detection.
Thailand’s good luck in attracting investment in the medical sector is largely due to two key factors.
One is the series of incentives presented through the BOI to eligible Thai and foreign companies, adding tax exemptions of up to thirteen years and prudent visas that allow expatriate researchers and other key painters and their families to remain in the country for up to 4 years. Years. Another is Thailand’s record, either to involve the spread of COVID-19 and to actively paint vaccines.
Since the beginning of the pandemic, Thailand has been praised through the foreign network for the very low infection rate among its 70 million inhabitants. During the same period, Thailand was also one of the first middle-income countries to initiate clinical trials in a household. -COVID-19 vaccine grown.
In addition to the oxford-mahidol global trial on hydroxychloroquine and chloroquine, Thai universities and biotechnology are running at least 3 candidate vaccines.
As a component of the most complex vaccine studies, Chula Vaccine Research Center at Chula University is about to begin human trials of a vaccine that has already been effectively tested in mice and monkeys.
Since its founding 15 years ago, Chula VRC has worked quietly on vaccines to combat the scourges of fitness such as HIV and dengue, in collaboration with several U. S. government and educational institutions. U. S. , the National Institute of Health and the University of Pennsylvania.
Dr. Kiat said his team will also participate in a one-moment review in Chulalongkorn in which Dr. Thirivat Hemachudha of the Thai Red Cross Center for Health Sciences for Emerging Infectious Diseases, in collaboration with Baiya Phytopharm, a graduate of sciences University’s Faculty of Pharmaceuticals, has developed a prospective vaccine that uses another generation derived from plant proteins. “It’s wonderful to have more than one candidate vaccine in Thailand among 180 applicants worldwide,” says Dr Kiat.
Scientist from Chula Vaccine Research Center is running for one of Thailand’s Covid-19 vaccine candidates
At the same time, Bionet Asia, a French-Thai joint venture founded in Bangkok, is running its own vaccine and is able to manufacture millions of doses of the first approved Thai candidate vaccines.
Founded in 2001 through French and Thai partners who in the past worked with Western pharmaceutical companies, Bionet Asia opened a study and progression center in Bangkok in 2009. Since then, she has developed vaccines to fight infectious diseases such as whoorine cough, rabies, meningitis. and dengue, the latter in collaboration with the Pasteur Institute in Paris.
This year, Bionet suspended all other paintings to concentrate its 250 painters on the progression and production of a recombinant DNA technology of the COVID-19 vaccine.
ONLINE ADVERTISING
Contact: Sirintip Yutika Mobile 80818 8187
Email: [email protected]